Sangamo Therapeutics Inc.

12/12/2021 | Press release | Distributed by Public on 12/12/2021 08:28

Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)

Read this content
The text version of this document is not available. You can access the original document here.